Fulltext

Ebselen Improves Ischemia-Reperfusion Injury After Rat Lung Transplantation

Hamacher, Jürg ; Stammberger, Uz ; Weber, Elvira ; Lucas, Rudolf ; Wendel, Albrecht

In: Lung, 2009, vol. 187, no. 2, p. 98-103

Aggiungi alla tua lista
    Titre
    • Ebselen Improves Ischemia-Reperfusion Injury After Rat Lung Transplantation
    Auteur
    • Hamacher, Jürg. Biochemical Pharmacology, University of Konstanz, Konstanz, Germany
    • Stammberger, Uz. Division of General Thoracic Surgery, University Hospital Inselspital, Bern, Switzerland
    • Weber, Elvira. Biochemical Pharmacology, University of Konstanz, Konstanz, Germany
    • Lucas, Rudolf. Biochemical Pharmacology, University of Konstanz, Konstanz, Germany
    • Wendel, Albrecht. Biochemical Pharmacology, University of Konstanz, Konstanz, Germany
    Type de document
    • Postprint
    Identifiant OAI-PMH
    • oai:doc.rero.ch:319391
    Summary
    The heterocyclic organic compound ebselen (2-phenyl-1,2-benizsoselenazol-3(2H)-one) is a glutathione peroxidase mimick with protective properties against oxidative injury. Ebselen also has anti-inflammatory activity, including attenuation of tumor necrosis factor release and increase of interleukin-10, as shown invivo, in inflammatory and ischemia-reperfusion injuries, including those of the lung. This study was designed to assess its effect on severe ischemia-reperfusion injury in a model of left-sided rat lung isotransplantation. Orthotopic single left-sided lung allotransplantation (Wistar to Wistar) was performed in female rats after a total ischemic time of 18h. In nine recipients given 500mg/kg oral ebselen 1h before transplantation, graft PaO2/FiO2 was improved 24h after transplantation, as evidenced with a mean (standard deviation) PaO2 of 139 (61) mmHg vs. eight controls with 65 (33) mmHg (p=0.009). Bronchoalveolar PMN count was reduced to approximately 50% in the ebselen group compared with controls, whereas no difference in the tumor necrosis factor content was found. We conclude that the improvement of lung function in ebselen-treated transplanted rats is mainly the result of the anti-inflammatory activity of the drug during reperfusion